Evidence map›Paper›PMID 26857460›Full record

Trial reportScientific reports2016

Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.

G Marziali, M Signore, M Buccarelli, S Grande, A Palma, M Biffoni, A Rosi, Q G D'Alessandris, M Martini, L M Larocca and 3 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

G MarzialiDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
M SignoreDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
M BuccarelliDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
S GrandeDepartment of Technology and Health, Istituto Superiore di Sanità, Rome, Italy.
A PalmaDepartment of Technology and Health, Istituto Superiore di Sanità, Rome, Italy.
M BiffoniDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
A RosiDepartment of Technology and Health, Istituto Superiore di Sanità, Rome, Italy.
Q G D'Alessandrisnstitute of Neurosurgery, Università Cattolica del Sacro Cuore, Rome, Italy.
M MartiniInstitute of Anatomic Pathology, Università Cattolica del Sacro Cuore, Rome, Italy.
L M LaroccaInstitute of Anatomic Pathology, Università Cattolica del Sacro Cuore, Rome, Italy.
R De MariaRegina Elena National Cancer Institute, Rome, Italy.
R Pallininstitute of Neurosurgery, Università Cattolica del Sacro Cuore, Rome, Italy.
L Ricci-VitianiDepartment of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is one of the deadliest human cancers. Because of the extremely unfavorable prognosis of GBM, it is important to develop more effective diagnostic and therapeutic strategies based on biologically and clinically relevant subclassification systems. Analyzing a collection of seventeen patient-derived glioblastoma stem-like cells (GSCs) by gene expression profiling, NMR spectroscopy and signal transduction pathway activation, we identified two GSC clusters, one characterized by a pro-neural-like phenotype and the other showing a mesenchymal-like phenotype. Evaluating the levels of proteins differentially expressed by the two GSC clusters in the TCGA GBM sample collection, we found that SRC activation is associated with a GBM subgroup showing better prognosis whereas activation of RPS6, an effector of mTOR pathway, identifies a subgroup with a worse prognosis. The two clusters are also differentiated by NMR spectroscopy profiles suggesting a potential prognostic stratification based on metabolic evaluation. Our data show that the metabolic/proteomic profile of GSCs is informative of the genomic/proteomic GBM landscape, which differs among tumor subtypes and is associated with clinical outcome.

Indexed as

Gene Expression Regulation, NeoplasticDisease-Free SurvivalFemaleGlioblastomaHumansMaleNeoplasm ProteinsNeoplastic Stem CellsNuclear Magnetic Resonance, BiomolecularProteomicsSurvival RateNeoplasm Proteins

Identifiers

PMID26857460
PMCPMC4746700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.